Reuters logo
BRIEF-Intellipharmaceutics provides operational update on its Rexista(TM) program
September 5, 2017 / 6:52 PM / 17 days ago

BRIEF-Intellipharmaceutics provides operational update on its Rexista(TM) program

Sept 5 (Reuters) - Intellipharmaceutics International Inc :

* Intellipharmaceutics provides operational update

* Currently anticipate Rexista program​ study will take nine months from commencement to complete

* Is in process of commencing its planned Category 3 study to support certain label claims for Rexista(TM)​

* Trial date for previously announced patent litigation by Purdue against co regarding Rexista(TM) set for Oct 22, 2018​

* ‍FDA is stayed from granting approval of Rexista until August 24, 2019​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below